JP2022501402A5 - - Google Patents
Info
- Publication number
- JP2022501402A5 JP2022501402A5 JP2021517437A JP2021517437A JP2022501402A5 JP 2022501402 A5 JP2022501402 A5 JP 2022501402A5 JP 2021517437 A JP2021517437 A JP 2021517437A JP 2021517437 A JP2021517437 A JP 2021517437A JP 2022501402 A5 JP2022501402 A5 JP 2022501402A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- binding construct
- composition
- patient
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218898A JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738938P | 2018-09-28 | 2018-09-28 | |
| US62/738,938 | 2018-09-28 | ||
| US201962826606P | 2019-03-29 | 2019-03-29 | |
| US62/826,606 | 2019-03-29 | ||
| PCT/US2019/053642 WO2020069433A1 (en) | 2018-09-28 | 2019-09-27 | Cd8 imaging constructs and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Division JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501402A JP2022501402A (ja) | 2022-01-06 |
| JP2022501402A5 true JP2022501402A5 (https=) | 2022-10-05 |
| JPWO2020069433A5 JPWO2020069433A5 (https=) | 2022-10-05 |
Family
ID=69949940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517437A Pending JP2022501402A (ja) | 2018-09-28 | 2019-09-27 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220001043A1 (https=) |
| EP (2) | EP4205769A1 (https=) |
| JP (2) | JP2022501402A (https=) |
| KR (1) | KR20210087938A (https=) |
| CN (2) | CN113166255A (https=) |
| AU (1) | AU2019351264A1 (https=) |
| CA (1) | CA3113080A1 (https=) |
| WO (1) | WO2020069433A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2019236684A1 (en) | 2018-06-08 | 2019-12-12 | Imaginab, Inc. | Antigen binding constructs to cd4 |
| GB2584086A (en) * | 2019-05-17 | 2020-11-25 | Univ Oxford Innovation Ltd | A method for identity validation and quality assurance of quantitative magnetic resonance imaging protocols |
| CA3195886A1 (en) * | 2020-09-17 | 2022-03-24 | Sunnybay Biotech, Inc | Herv-k antibody therapeutics |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4644874A1 (en) | 2022-12-26 | 2025-11-05 | FUJIFILM Corporation | Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit |
| CN116130131B (zh) * | 2022-12-30 | 2026-02-06 | 中国核动力研究设计院 | 一种一回路压力边界泄漏辐射监测装置及其监测方法 |
| JP2026502532A (ja) * | 2023-01-12 | 2026-01-23 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞及びｎｋ細胞悪性腫瘍の免疫療法のためのｃｄ８発現及びキメラ抗原受容体の遮断 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| US12086990B1 (en) * | 2024-04-23 | 2024-09-10 | MultiFunctional Imaging LLC | Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| EP1877399A1 (en) * | 2005-04-26 | 2008-01-16 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP4877766B2 (ja) | 2006-08-25 | 2012-02-15 | 独立行政法人放射線医学総合研究所 | 陽電子放射断層撮像装置及び放射線検出器 |
| US20130137975A1 (en) * | 2010-02-09 | 2013-05-30 | OSI Pharmaceuticals, LLC | Pet imaging |
| CA2826251A1 (en) | 2011-02-03 | 2012-08-09 | Integrated Diagnostics, Inc. | Psa capture agents, compositions, methods and preparation thereof |
| US8993971B2 (en) | 2011-06-15 | 2015-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | High resolution positron emission tomography |
| AU2012282678B2 (en) | 2011-07-11 | 2016-03-03 | California Institute Of Technology | Akt-specific capture agents, compositions, and methods of using and making |
| US8710180B2 (en) | 2011-08-31 | 2014-04-29 | Indi Molecular, Inc. | VEGF-specific capture agents, compositions, and methods of using and making |
| JP2015508903A (ja) * | 2012-02-28 | 2015-03-23 | コーネル ユニヴァーシティー | 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014074907A1 (en) | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| CN105979872A (zh) | 2013-09-25 | 2016-09-28 | 理查德·R·布莱克 | 正电子发射断层摄影数据的病人特异性分析 |
| DE102014200303B4 (de) | 2014-01-10 | 2015-10-29 | Siemens Aktiengesellschaft | Verfahren zur Durchführung einer Positronenemissionstomographie in einer Hybridanlage und entsprechende Hybridanlage |
| US10844122B2 (en) * | 2015-05-06 | 2020-11-24 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
| CN105395209B (zh) | 2015-12-01 | 2018-10-02 | 沈阳东软医疗系统有限公司 | 一种正电子发射断层扫描成像系统及方法 |
| CN115109120A (zh) | 2016-04-04 | 2022-09-27 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
| WO2017214766A1 (zh) | 2016-06-12 | 2017-12-21 | 上海联影医疗科技有限公司 | 正电子发射断层成像系统及其图像重建方法 |
| CN111295394B (zh) * | 2017-08-11 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 抗cd8抗体及其用途 |
-
2019
- 2019-09-27 KR KR1020217012365A patent/KR20210087938A/ko active Pending
- 2019-09-27 CN CN201980079379.0A patent/CN113166255A/zh active Pending
- 2019-09-27 US US17/280,137 patent/US20220001043A1/en active Pending
- 2019-09-27 AU AU2019351264A patent/AU2019351264A1/en active Pending
- 2019-09-27 EP EP22182384.2A patent/EP4205769A1/en active Pending
- 2019-09-27 CN CN202211648348.2A patent/CN116271117A/zh active Pending
- 2019-09-27 WO PCT/US2019/053642 patent/WO2020069433A1/en not_active Ceased
- 2019-09-27 JP JP2021517437A patent/JP2022501402A/ja active Pending
- 2019-09-27 EP EP19866804.8A patent/EP3856786A4/en active Pending
- 2019-09-27 CA CA3113080A patent/CA3113080A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218898A patent/JP2025060696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501402A5 (https=) | ||
| JPWO2020069433A5 (https=) | ||
| Christensen et al. | Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody | |
| Stillebroer et al. | Phase 1 radioimmunotherapy study with lutetium 177–labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma | |
| JP7839135B2 (ja) | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 | |
| Muros et al. | Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels | |
| Lockhart et al. | Phase 1 evaluation of [64Cu] DOTA-patritumab to assess dosimetry, apparent receptor occupancy, and safety in subjects with advanced solid tumors | |
| Burvenich et al. | Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a | |
| Lindenberg et al. | Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging | |
| JP2021510697A5 (https=) | ||
| Wei et al. | HER2-targeted multimodal imaging of anaplastic thyroid cancer | |
| Zhu et al. | Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy | |
| Stahl et al. | Positron emission tomography as a tool for translational research in oncology | |
| Liu et al. | [64Cu] Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window | |
| Tseng et al. | The synergy of 177Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model | |
| EP2795317B1 (en) | Composition for use in a method for cancer selection | |
| Raderer et al. | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer | |
| TW202120129A (zh) | 用作為診療劑之放射標記grpr拮抗劑 | |
| Vahidfar et al. | Recent Advances of Copper-64 Based Radiopharmaceuticals in | |
| Raderer et al. | Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy | |
| Singh et al. | Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma | |
| Xu et al. | Radiopharmaceuticals in nasopharyngeal cancer | |
| Kameswaran et al. | Preclinical evaluation of 131I-Bevacizumab–A prospective agent for radioimmunotherapy in VEGF expressing cancers | |
| Draisma et al. | Gallium-67 as a Tumor-seeking Agent in Lymphomas-a Review | |
| US11357874B2 (en) | Tumor targeted radionuclide therapy and molecular imaging of HER2+ cancers and other neoplasms |